Back to discover
Disease

Neurofibrosarcoma

Late-stage therapeutic developmentEmerging research
1
Publications
4
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

Research2023-09-01Clinical cancer research : an official journal of the American Association for Cancer Research

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical trials

3 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
4
All trials
1
Active
1
Late-stage
3
Completed

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · 23 cites
Recent publications

CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · 23 cites
Major themes1
  • Neurofibrosarcoma1
Leading journals1
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers8
  • Breheny P1
  • Brockman QR1
  • Calizo A1
  • Chimenti MS1
  • Darbro BW1
  • Dodd RD1
  • Hirbe AC1
  • Kaemmer CA1
Affiliations (unnormalised)6
  • Carver College of Medicine1
  • College of Public Health1
  • Holden Comprehensive Cancer Center1
  • Iowa Institute of Human Genetics1
  • Johns Hopkins University1
  • Leroy T. Canoles Jr. Cancer Center1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A malignant tumor that arises from small cutaneous nerves, is locally aggressive, and has a potential for metastasis. Characteristic histopathologic features include proliferating atypical spindle cells with slender wavy and pointed nuclei, hypocellular areas, and areas featuring organized whorls of fibroblastic proliferation. The most common primary sites are the extremities, retroperitoneum, and trunk. These tumors tend to present in childhood, often in association with NEUROFIBROMATOSIS 1. (From DeVita et al., Cancer: Principles & Practice of Oncology, 5th ed, p1662; Mayo Clin Proc 1990 Feb;65(2):164-72)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.